ARA290 Peptide

ARA290 Peptide Powder | GMP Research Peptide Manufacturer in China | EPO-Derived Peptide API Supply

Key Product Highlights:

• EPOR/CD131 tissue-protective receptor targeting peptide
• Supports ischemia–hypoxia research models and tissue-protective signaling studies
• Regulates macrophage inflammatory polarization
• Used in neuronal and vascular endothelial pathway research
• Supports microcirculation-related mechanism studies
• Low endotoxin, stable GMP-grade lyophilized API
• High batch-to-batch consistency with full traceability

ARA290 peptide is a synthetic, small-molecule erythropoietin (EPO)-derived mimetic peptide produced via advanced Fmoc solid-phase peptide synthesis (SPPS). It precisely replicates the native peptide sequence and is supplied as a sterile lyophilized research-grade API.

Unlike full-length erythropoietin, ARA290 selectively targets the EPOR/CD131 heteroreceptor complex responsible for tissue-protective signaling, without stimulating erythropoiesis. This significantly reduces hematopoietic interference in experimental models.

It is widely applied in ischemic injury research, neuroprotection studies, and microcirculation mechanism investigations. The peptide exhibits stable aqueous solubility and reproducible biological activity in both in vitro and in vivo systems, ensuring high experimental consistency.

All manufacturing processes are performed under GMP-compliant cleanroom conditions, ensuring controlled impurities, low endotoxin levels, and reliable batch reproducibility.

The ARA290 peptide GMP supplier bulk research-grade standardized formulation ensures reproducibility across global academic and pharmaceutical laboratories.

• Highly selective receptor targeting (EPOR/CD131 only)
• Minimal interference with erythropoiesis pathways
• Strong anti-inflammatory polarization modulation
• Multi-tissue protective effects (nerve, vascular, cardiac, renal)
• Excellent solubility in aqueous and buffer systems
• Low endotoxin and minimal cytotoxic interference
• Moderate enzymatic stability for long-term experimental use

• Ischemia–hypoxia injury model research
• Regulation of macrophage inflammatory polarization
• Neuronal signaling and neurobiology research
• Microvascular endothelial pathway studies
• Activation of tissue-protective, non-erythropoietic signaling pathways

• Precision Fmoc-SPPS peptide synthesis platform
• Multi-step chromatographic purification system
• GMP-certified cleanroom facility
• Scalable production from milligram to kilogram levels
• High batch-to-batch reproducibility and stability
• Technical support for research applications

1. Anti-apoptotic signaling pathway activation
2. Macrophage anti-inflammatory polarization regulation
3. Endothelial cell repair and angiogenesis support
4. Neuronal membrane stabilization under hypoxic stress

ARA290 Peptide selectively activates EPOR/CD131 tissue-protective pathways without triggering hematopoietic EPOR signaling, minimizing experimental interference and improving data reliability.

1. GMP-compliant cleanroom production system
2. High-quality peptide raw material sourcing
3. Multi-stage in-process quality control
4. Batch release only after COA approval
5. 2-year retained sample traceability system
6. Complete export documentation (COA / MSDS / non-hazard certificate)
7. Vacuum-sealed moisture-proof packaging for stability

Q1: What is Ara 290 used for?

A: Ara290 is exclusively for preclinical laboratory research, mainly in studies of ischemic tissue injury, peripheral neuropathy, microcirculation regulation and inflammatory immune modulation.

Q2: How long does it take Ara 290 to work?

A: Its observable biological effects vary by animal model, dosage and experimental setup; measurable changes usually emerge within several hours to days in preclinical in vivo studies.

Q3: What is the best peptide for neuropathy?

A: There is no universal "best" option. Ara290 is a well-documented candidate for neuropathy research due to its neuroprotective and microcirculation-improving properties in preclinical trials.

Q4: Is peptide ara 290 fda approved?

A: No, Ara290 has not obtained FDA approval for human clinical use; it is only permitted for laboratory research purposes.

Hot Tags: ara290 peptide, China ara290 peptide manufacturers, suppliers, factory, Albiglutide Powder, LL 37 Peptide Powder, Oxytocin Powder, Protirelin Powder, Retatrutide Raw Powder, Tirzepatide Peptide Raw Powder